Send to

Choose Destination
Bull Exp Biol Med. 2008 Jul;146(1):133-8.

Induction of antiidiotypic immune response with autologous T-cell vaccine in patients with multiple sclerosis.

Author information

Research Institute of Clinical Immunology, Siberian Division of Russian Academy of Medical Sciences, Novosibirsk, Russia.


Patients with different forms of multiple sclerosis were treated with a vaccine consisting of myelin-reactive T cells. It was found that after this treatment, lymphocytes from patients acquired the capacity to generate antiidiotypic proliferative response directed towards myelin-reactive T cells. The serum concentration of IFN-gamma decreased about 2-fold 1.5-2.0 years after the start of vaccine therapy, whereas the concentration of IL-4 increased 2-3 fold. Myelin-reactive proliferative activity of peripheral blood mononuclear cells also decreased. The results of the 2-year follow-up study revealed no side effect of T-cell vaccination in patients with cerebrospinal form of multiple sclerosis and demonstrated its possible clinical efficiency in the treatment of this disease at early stages.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center